Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Combination Therapy With Myo-inositol and Folic Acid Versus Myo-inositol Alone

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2012 by Catholic University of the Sacred Heart.
Recruitment status was  Recruiting
Information provided by (Responsible Party):
Maurizio Guido, Catholic University of the Sacred Heart Identifier:
First received: March 13, 2012
Last updated: March 14, 2012
Last verified: March 2012

Previous studies have demonstrated that Myo-inositol is capable of restoring spontaneous ovarian activity, and consequently fertility, in most patients with PCOS. The aim of our study is to investigate the role of folic acid conteined in the inositol preparation. The study group included 50 patients, randomly allocated to subgroup A (myo-inositol 1500 gr) and subgroup B (myo-inositol 2000 gr + folic acid 200 mcg). The investigation include menstrual pattern and hirsutism score evaluation, hormonal assays, oral glucose tolerance test, euglycemic hyperinsulinaemic clamp and lipide profile at baseline and after six months of treatment.

Condition Intervention
Polycystic Ovary Syndrome
Menstrual Irregularity
Drug: myo-inositol 1500 gr
Drug: myo-inositol 2000 gr + folic acid 200 mcg

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Combination Therapy With Myo-inositol and Folic Acid Versus Myo-inositol Alone: Effects of Six Months Treatment on Clinical, Endocrine and Metabolic Features in Obese Women With Polycystic Ovary Syndrome

Resource links provided by NLM:

Further study details as provided by Catholic University of the Sacred Heart:

Primary Outcome Measures:
  • number of cycles in six months of therapy [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    We'll estimate the efficacy of the two treatments on the ovarian function and menstrual pattern.

Secondary Outcome Measures:
  • effects on oral glucose tollerance test [ Time Frame: six months ] [ Designated as safety issue: No ]
  • effects on hoormonal assay [ Time Frame: 6 months ]
  • effects oon lipide profile [ Time Frame: 6 months ]

Estimated Enrollment: 50
Study Start Date: January 2012
Arms Assigned Interventions
Active Comparator: myo-inositol 1500 gr
6 months treatment with myo-inositol 1500 gr
Drug: myo-inositol 1500 gr
Active Comparator: myo-inositol 2000gr + folic acid 200 mcg Drug: myo-inositol 2000 gr + folic acid 200 mcg


Ages Eligible for Study:   18 Years to 35 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • women with PCOS diagnosed in accordance with Rotterdam Consensus Conference Criteria 2003
  • BMI > 25 kg/m2
  • age 18-35 years

Exclusion Criteria:

  • pregnancy
  • significant liver or renal impairment
  • other hormonal dysfunctions (hypothalamic, pituitary, thyroidal or adrenal causes for the clinical signs)
  • neoplasms
  • unstable mental illness
  • diagnosis of diabetes mellitus or impaired glucose tolerance
  • use of drugs able to interfere with gluco-insulinaemic metabolism for at least three months prior entering the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01555190

Contact: Antonio Lanzone, professor 0039063057794

Catholic University of Sacred Heart Recruiting
Rome, Italy, 00168
Contact: Maurizio Guido, Medical Doctor    00390630156013   
Principal Investigator: Maurizio Guido, doctor         
Sponsors and Collaborators
Catholic University of the Sacred Heart
  More Information

No publications provided

Responsible Party: Maurizio Guido, medical doctor, Catholic University of the Sacred Heart Identifier: NCT01555190     History of Changes
Other Study ID Numbers: 000102012
Study First Received: March 13, 2012
Last Updated: March 14, 2012
Health Authority: Italy: Catholic University of Sacred Heart

Keywords provided by Catholic University of the Sacred Heart:
folic acid

Additional relevant MeSH terms:
Polycystic Ovary Syndrome
Adnexal Diseases
Endocrine System Diseases
Genital Diseases, Female
Gonadal Disorders
Ovarian Cysts
Ovarian Diseases
Pathologic Processes
Folic Acid
Vitamin B Complex
Growth Substances
Hematologic Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Vitamins processed this record on November 20, 2014